LysRs-IN-1

CAS No. 281676-77-5

LysRs-IN-1( 9-carboxymethylguanine )

Catalog No. M26286 CAS No. 281676-77-5

LysRs-IN-1 is a Lysyl-tRNA synthetase (LysRs) inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 33 In Stock
5MG 57 In Stock
10MG 91 In Stock
25MG 155 In Stock
50MG 223 In Stock
100MG 319 In Stock
200MG 437 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    LysRs-IN-1
  • Note
    Research use only, not for human use.
  • Brief Description
    LysRs-IN-1 is a Lysyl-tRNA synthetase (LysRs) inhibitor.
  • Description
    LysRs-IN-1 is a Lysyl-tRNA synthetase (LysRs) inhibitor.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    9-carboxymethylguanine
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    MT1 receptor| MT2 receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    281676-77-5
  • Formula Weight
    209.165
  • Molecular Formula
    C7H7N5O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 83.33 mg/mL (398.40 mM)
  • SMILES
    Nc1nc2n(CC(O)=O)cnc2c(=O)[nH]1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Descamps-Fran?ois C, et al. Design and synthesis of naphthalenic dimers as selective MT1 melatoninergic ligands. J Med Chem. 2003 Mar 27;46(7):1127-9.
molnova catalog
related products
  • Arg-Gly-Asp-Ser (TFA...

    Arg-Gly-Asp-Ser (TFA) is an integrin binding sequence that inhibits integrin receptor function.

  • Lefradafiban

    Lefradafiban(BIBU-104) is an oral platelet glycoprotein IIb/IIIa receptor antagonist for the study of angina pectoris and acute coronary syndromes.

  • IGS-1.76

    IGS-1.76 shows a significantly increased affinity for hNCS-1 and is able to modulate the hNCS-1/Ric8a interaction efficiently.IGS-1.76 efficiently inhibits the human NCS-1/Ric8a complex.IGS-1.76, which efficiently inhibits the human NCS-1/Ric8a complex with improved binding potency.?